Effects of opiates and HIV proteins on neurons: The role of Ferritin heavy chain and a potential for synergism

Current HIV Research

Volumn 10, Issue 5, 2012, Pages 453-462

  Festa, Lindsay ^a   Meucci, Olimpia ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

CXCR4; Ferritin; Gp120; HIV; Neuron; Opiates; Tat

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FERRITIN; FERRITIN HEAVY CHAIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; MU OPIATE RECEPTOR; OPIATE; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NERVE INJURY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; ANALGESICS, OPIOID; DISEASE PROGRESSION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; NEURONS; OPIOID-RELATED DISORDERS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866332761     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802138751     Document Type: Review

References (134)

1. Prejean J, Song R, Hernandez A, et al. Estimated HIV Incidence in the United States, 2006-2009. PLoS One 2011; 6: e17502.
2. Center for Disease Control. Drug-associated HIV Transmission Continues in the United States. Atlanta: US Department of Health and Human Services 2007.
3. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 2005; 191: 886-889.
4. Hauser KF, El-Hage N, Buch S, et al. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol 2006; 1: 98-105.
5. Bokhari SM, Hedge R, Callen S, et al. Morphine Potentiates Neuropathogenesis of SIV Infection in Rhesus Macaques. J Neuroimmune Pharmacol 2011; 6: 626-639.
6. Cooper DA. Life and death in the cART era. Lancet 2008; 372: 266-267.
7. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-298.
8. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
9. Vivithanaporn P, Gill MJ, Power C. Impact of current antiretroviral therapies on neuroAIDS. Expert Rev Anti Infect Ther 2011; 9: 371-374.
10. Lawrence DM, Major EO. HIV-1 and the brain: connections between HIV-1 associated dementia, neuropathology and neuroimmunology. Microbes Infect 2002; 4: 301-308.
11. Haase AT. Pathogenesis of lentivirus infections. Nature 1986; 322: 130-136.
12. Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3: 28.
13. Reger M, Welsh R, Razani J, Martin DJ, Boone KB. A metaanalysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc 2002; 8: 410-424.
14. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27: 86-92.
15. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1798-1799.
16. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 2010; 75: 1150-1158.
17. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410: 988-994.
18. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol 2010: 67: 699-714.
19. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999; 19:129-150.
20. Glass JD, Johnson RT. Human immunodeficiency and the brain. Annu Rev Neurosci 1996; 19: 1-26.
21. Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA. Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 1992; 51: 585-593.
22. Thompson KA, McArthur JC, Wesselingh SL. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Ann Neurol 2001; 49: 745-752.
23. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 1997; 42: 963-972.
24. Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998; 4: 619-626.
25. Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE. Upregulation of microglia in drug users with and without presymptomatic HIV infection. Neuropathol Appl Neurobiol 1999; 25: 369-379.
26. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Does drug abuse alter microglial phenotype and cell turnover in the context of advancing HIV infection? Neuropathol Appl Neurobiol 2005; 31: 325-338.
27. Bell JE, Arango JC, Anthony IC. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illict drugs. J Neuroimmune Pharmacol 2006; 1: 182-191.
28. Brew BJ, Bhalla RB, Fleisher M, et al. Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. Neurology 1989; 39: 830-834.
29. Lindl KA, Marks DR, Kolson DL, Jordan-Scuitto KL. HIVassociated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 2010; 5: 294-309.
30. Genis P, Jett M, Bernton EW, et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 1992; 176: 1703-1718.
31. Giulian D, Wendt E, Vaca K, Noonan CA. The envelope glycoprotein of human immunodeficiency virus type 1 stimulate release of neurotoxins from monocytes. Proc Natl Acad Sci USA 1993; 90: 2769-2773.
32. Lipton SA. AIDS-related dementia and calcium homeostasis. Ann NY Acad Sci 1994; 747: 205-224.
33. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990; 248: 364-367.
34. Dawson VL, Dawson TM, Uhl GR, Snyder SH. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 1993; 90: 3256-3259.
35. Medders KE, Sejbuk NE, Maung R, Desai MK, Kaul M. Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J Immunol 2010; 185: 4883-4895.
36. Singh IN, El-Hage N, Campbell ME, et al. Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons. Neuroscience 2005; 135: 781-790
37. Garden GA, Budd SL, Tsai E, et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002; 22: 4015-4024.
38. Acquas E, Bachis A, Nosheny RL, Cernak I, Mocchetti I. Human immunodeficiency virus type 1 protein gp120 causes neuronal cell death in the rat brain by activating caspases. Neurotox Res 2004; 5: 605-615.
39. Bachis A, Major EO, Mocchetti I. Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. J Neurosci 2003; 23: 5715-5722.
40. Nosheny RL, Bachis A, Acquas E, Mocchetti I. Human immunodeficiency virus type 1 glycoprotein gp120 reduces the level of brain-derived neurotrophic factor in vivo: potential implication for neuronal cell death. Eur J Neurosci 2004; 20: 2857-2864.
41. Pulliam L, Zhou M, Stubblebine M, Bitler CM. Differential modulation of cell death proteins in human brain cells by tumor necrosis factor alpha and platelet activating factor. J Neurosci Res 1998; 54: 530-538.
42. Meucci O, Miller RJ. Gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-beta 1. J Neurosci 1996; 16: 4080-4088.
43. Letterio JJ, Roberts AB. Regulation of immune responses by TGFbeta. Annu Rev Immunol 1998; 16: 137-161.
44. Wesselingh SL, Power C, Glass JD, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993; 33: 576-582.
45. Wiley CA, Baldwin M, Achim CL. Expression of HIV regulatory and structural mRNA in the central nervous system. AIDS 1996; 10: 843-847.
46. Bonavia R, Bajetto A, Barbero S, Albini A, Noonan DM, Schettini G. HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat neurons. Biochem Biophys Res Commun 2001; 288: 301-308.
47. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A. Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995; 37: 373-380.
48. Cheng J, Nath A, Knudsen B, et al. Neuronal excitatory properties of human immunodeficiency virus type Tat protein. Neuroscience 1998; 82: 97-106.
49. Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem 2001; 78: 457-467.
50. O'Donnell LA, Agrawal A, Jordan-Sciutto KL, et al. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 2006; 26: 981-990.
51. Haughey NJ, Holden CP, Nath A, Geiger JD. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J Neurochem 1999; 73: 1363-1374.
52. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-99.
53. Singh IN, Goody, RJ, Dean C, et al. Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-2 and endonuclease G. J Neurovirol 2004; 10: 141-151.
54. Liu Y, Jones M, Hingtgen CM, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000; 6: 1380-1387.
55. Eugenin EA, King JE, Nath A, et al. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci USA 2007; 104: 3438-3443.
56. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature 1998; 391: 240.
57. Hesselgesser J, Halks-Miller M, DelVecchio V, et al. CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol 1997; 7: 112-121.
58. Clapham PR, McKnight A. HIV-1 receptors and cell tropism. Br Med Bull 2001; 58: 43-59.
59. Petito CK, Roberts B, Cantando JD, Rabinstein A, Duncan R. Hippocampal injury and alterations in neuronal chemokine coreceptor expression in patients with AIDS. J Neuropathol Exp Neurol 2001; 60: 377-385.
60. Lazarini F, Tham TN, Casanova P, Arenzana-Seisdedos F, Dubois-Dalcq M. Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia 2003; 42: 138-148.
61. Li M, Ransohoff RM. Multiple roles of chemokine CXL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol 2008; 84: 116-131.
62. Khan MZ, Brandimarti R, Patel JP, et al. Apoptotic and antiapoptotic effects of CXCR4: is it a matter of intrinsic efficacy? Implications for HIV neuropathogenesis. AIDS Res Hum Retroviruses 2004; 20: 1063-1071.
63. Khan MZ, Brandimarti R, Musser BJ, Resue DM, Fatatis A, Meucci O. The chemokine receptor CXCR4 regulates cell-cycle proteins in neurons. J Neurovirol 2003; 9: 300-314.
64. Khan MZ, Brandimarti R, Shimizu S, Nicolai J, Crowe E, Meucci O. The chemokine CXCL12 promotes survival of postmitotic neurons by regulating Rb protein. Cell Death Differ 2008; 15: 1663-1672.
65. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
66. Nicolai J, Burbassi S, Rubin J, Meucci O. CXCL12 inhibits expression of NMDA receptor's NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival. Cell Death Dis 2010; 1: e33.
67. Zhang K, McQuibban GA, Silva C, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 2003; 6: 1064-1071.
68. Vergote D, Butler GS, Ooms M, et al. Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc Natl Acad Sci USA 2006; 103: 19182-19187.
69. Lazarini F, Casanova P, Tham TN, et al. Differential signalling of the chemokine receptor CXCR4 by stromal cell-derived 1 and the HIV glycoprotein in rat neurons and astrocytes. Eur J Neurosci 2000; 12: 117-125.
70. Toth PT, Ren D, Miller RJ. Regulation of CXCR4 receptor dimerization by chemokine SDF-1alpha and the HIV-1 coat protein gp120: a fluorescence resonance energy transfer (FRET) study. J Pharmacol Exp Ther 2004; 310: 8-17.
71. Bardi G, Sengupta R, Khan MZ, Patel JP, Meucci O. Human immunodeficiency virus gp120-induced apoptosis of human neuroblastoma cells in the absence of CXCR4 internalization. J Neurovirol 2006; 12: 211-218.
72. Shimizu S, Khan MZ, Hippensteel RL, Parkar A, Raghupathi R, Meucci O. Role of transcription factor E2F1 in CXCR4-mediated neurotoxicity and HIV neuropathology. Neurobiol Dis 2007; 25: 17-26.
73. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998; 95: 14500-14505.
74. Pandey V, Bolsover SR. Immediate and neurotoxic effects of HIV protein gp120 act through CXCR4 receptor. Biochem Biophys Res Commun 2000; 274: 212-215.
75. Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998; 83: 63-69.
76. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J 2005; 7: E587-E591.
77. Zhang Y, Chen Q, Yu LC. Morphine: a protective or destructive role in neurons? Neuroscientist 2008; 14: 561-570.
78. Pasternak GW. Multiple opiate receptors: déjàv all over again. Neuropharmacology 2004; 47 Suppl 1: 312-323.
79. Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 1994; 45: 330-334.
80. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819-823.
81. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1999; 20: 19-26.
82. Polakiewicz RD, Schieferi SM, Gingras AC, Sonenberg N, Comb MJ. Mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem 1998; 273: 23534-23541.
83. Kramer HK, Simon EJ. Mu and delta-opioid receptor agonists induce mitogen-activated protein kinase (MAPK) activation in the absence of receptor internalization. Neuropharmacology 2000; 39: 1707-1719.
84. Meriney SD, Gray DB, Pilar G. Morphine-induced delay of normal cell death in the avian ciliary ganglion. Science 1985; 228: 1451-1453.
85. Ferrer-Alcón M, Garcia-Fuster MJ, La Harpe R, Garcia-Sevilla JA. Long-term regulation of signaling components of adenylyl cyclase and mitogen-activated protein kinase in the pre-frontal cortex of human opiate addicts. J Neurochem 2004; 90: 220-230.
86. Atici S, Cinel L, Cinel I, et al. Opioid neurotoxicity: comparison of morphine and tramadol in an experimental rat model. Int J Neurosci 2004; 114: 1001-1011.
87. Mao J, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002; 22: 7650-7661.
88. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology 2002; 42: 829-836.
89. Fan XL, Zhang JS, Zhang XQ, Ma L. Chronic morphine treatment and withdrawal induce up-regulation of c-Jun N-terminal kinase 3 gene expression in rat brain. Neuroscience 2003; 122: 997-1002.
90. Emeterio EP, Tramullas M, Hurle MA. Modulation of apoptosis in the mouse brain after morphine treatments and morphine withdrawal. J Neurosci Res 2006; 83: 1352-1361.
91. Yin D, Woodruff M, Zhang Y, et al. Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-kappaB pathways. J Neuroimmunol 2006; 174: 101-107.
92. Lamprecht R, LeDoux J. Structural plasticity and memory. Nat Rev Neurosci 2004; 4: 45-54.
93. Segal M. Dendritic spines, synaptic plasticity and neuronal survival: activity shapes dendritic spines to enhance neuronal viability. Eur J Neurosci 2010; 31: 2178-2184.
94. Robinson TE, Kolb B. Morphine alters the structure of neurons in the nucleus accumbens and neocortex of rats. Synapse 1999; 33: 160-166
95. Li Y, Wang H, Niu L, Zhou Y. Chronice morphine exposure alters the dendritic morphology of pyramidal neurons in visual cortex of rats. Neurosci Lett 2007; 418: 227-231.
96. Liao D, Lin H, Law PY, Loh HH. Mu-opioid receptors modulate stability of dendritic spines. Proc Natl Acad Sci USA 2005; 102: 1725-1730.
97. Zheng H, Zeng Y, Chu J, Kam AY, Loh HH, Law PY. Modulations of NeuroD activity contributes to the differential effects of morphine and fentanyl on dendritic spine stability. J Neurosci 2010; 30: 8102-8110.
98. Liao D, Grigoriants OO, Wang W, Wiens K, Loh HH, Law PY. Distinct effects of individual opioids on the morphology of spines depend on upon the internalization of mu opioid receptors. Mol Cell Neurosci 2007; 35: 456-469.
99. Liu Y, Blackbourn DJ, Chuang LF, Killam KF Jr, Chuang RY. Effects of in vivo and in vitro administration of morphine sulfate upon rhesus macaque polymorphonuclear cell phagocytosis and chemotaxis. J Pharmacol Exp Ther 1992; 263: 533-539.
100. Rogers TJ, Steele AD Howard OM, Oppenheim JJ. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann NY Acad Sci 2000; 917: 19-28.
101. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY. Heterodimerization and cross-desensitization between the muopioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 2004; 483: 175-186.
102. Szabo I, Chen XH, Xin L, et al. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Nat Acad Sci USA 2002; 99: 10276-10281.
103. Grimm MC, Ben-Baruch A, Taub DD, et al. Opiates transdeactivate chemokine receptors: delta and mu opiate receptormediated heterologous desensitization. J Exp Med 1998; 188: 317-325.
104. Steele AD, Szabo I, Bednar F, Rogers TJ. Interactions between opioid and chemokine receptors: heterologous desensitization. Cytokine Growth Factor Rev 2002; 13: 209-222.
105. Patel JP, Sengupta R, Bardi G, Khan MZ, Mullen-Przeworski A, Meucci O. Modulation of neuronal CXCR4 by the mu-opioid agonist DAMGO. J Neurovirol 2006; 12: 492-500.
106. Sengupta R, Burbassi S, Shimizu S, et al. Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons. J Neurosci 2009; 29: 2534-2544.
107. Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE, Nair MP. Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 2005; 115: 323-332.
108. Li R, Luo C, Mines M, Zhang J, Fan GH. Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain. J Biol Chem 2006; 281: 37616-37627.
109. Hintze KJ, Theil EC. Cellular regulation and molecular interactions of the ferritins. Cell Mol Life Sci 2006; 63: 591-600.
110. Torti FM, Torti SV. Regulation of ferritin genes and proteins. Blood 2002; 99: 3505-3516.
111. White K, Munro HN. Induction of ferritin subunit synthesis by iron is regulated at both the transcriptional and translational levels. J Biol Chem 1988; 263: 8938-8942.
112. Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord 2011; 17: 423-430.
113. Li L, Fang CJ, Ryan JC, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci USA 2010; 107: 3505-3510.
114. Surguladze N, Thompson KM, Beard JL, Connor JR, Fried MG. Interactions and reactions of ferritin with DNA. J Biol Chem 2004; 279: 14694-14702.
115. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless leg syndrome. Neurology 2003; 61: 304-309.
116. Quintana C, Guitierrez L. Could a dysfunction of ferritin be a determinant factor in the aetiology of some neurodegenerative diseases? Biochim Biophys Acta 2010; 1800: 770-782.
117. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci 2004; 1012: 193-208.
118. Deisenhammer F, Miller RF, Brink NS, Harrison MJ, Thompson EJ. Cerebrospinal fluid ferritin in HIV infected patients with acute neurological episodes. Genitourin Med 1997; 73: 181-183.
119. Pitcher J, Shimizu S, Burbassi S, Meucci O. Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS. J Neuroimmunol 2010; 224: 66-71.
120. Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 2010; 58: 1630-1639.
121. Bokhari SM, Yao H, Bethel-Brown C, et al. Morphine enhances Tat-induced activation in murine microglia. J Neurovirol 2009; 15: 219-228.
122. Fitting S, Xu R, Bull C, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010; 177: 1397-1410.
123. Gurwell JA, Nath A, Sun Q, et al. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 2001; 102: 555-563.
124. Pountney D, Trugnan G, Bourgeois M, Beaumont C. The identification of ferritin in the nucleus of K562 cells, and investigation of a possible role in the transcriptional regulation of adult beta-globin gene expression. J Cell Sci 1999; 112: 825-831.
125. Thompson KJ, Fried MG, Ye Z, Boyer P, Connor JR. Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci 2002; 2165-2177.
126. Surguladze N, Patton S, Cozzi A, Fried MG, Connor JR. Characterization of nuclear ferritin and mechanisms of translocation. Biochem J 2005; 388: 731-740.
127. Faniello MC, di Sanzo M, Quaresima B, et al. P53-mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y. Int J Biochem Cell Biol 2008; 40: 2110-2119.
128. Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM. Posttranscriptional modulation of iron homeostasis during p53-depedent growth arrest. J Biol Chem 2008; 283: 33911-33918.
129. Lee JH, Jang H, Cho EJ, Youn HD. Ferritin binds and activates p53 under oxidative stress. Biochem Biophys Res Commun 2009; 389: 399-394.
130. Khan MZ, Shimizu S, Patel JP, et al. Regulation of neuronal P53 activity by CXCR4. Mol Cell Neurosci 2005; 30: 58-66.
131. Fahmay M, Young SP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J 1993; 296: 175-181.
132. Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997; 90: 4979-4986.
133. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM. Ironindependent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci USA 1991; 88: 4946-4950.
134. Cozzi A, Levi S, Corsi B, et al. Role of iron and ferritin in TNFalpha-induced apoptosis in HeLa cells. FEBS Lett 2003; 537: 187-192.